Journal of Child

SUBMITINFORMATION
EnglishTürkçe

Research Article


DOI :10.26650/jchild.2025.1554292   IUP :10.26650/jchild.2025.1554292    Full Text (PDF)

Treosulfan-Based Conditioning Regimen for Allogeneic Hepatopoietic Stem Cell Transplantation in Children: A Single Center Experience

Nihan Bayram, Yöntem Yaman, Kürşat Özdilli, Işık Odaman Al, Serdar Nepesov, Murat Elli, Seniye Sema Anak

Objective: Treosulfan is an alkylating agent whose use is increasing in HSCT conditioning regimens. Studies have highlighted its efficacy alongside its low toxicity profile. In this single-center study, we retrospectively report our experience and results with treosulfan in pediatric stem cell conditioning regimens.

Methods: Fifty-seven patients who underwent stem cell transplantation with a treosulfan-based conditioning regimen between September 2017 and April 2023 at the Istanbul Medipol University Pediatric Bone Marrow Transplantation Unit were included in the study. Treosulfan doses were determined based on age (under 1 year: 10g/m²/day; 1-2 years: 12g/m²/day; over 2 years: 14g/m²/day for 3 days).

Results: Of the 57 patients, 27 (47%) experienced acute GVHD and 3 (5.2%) experienced chronic GVHD. Of the 27 patients who had acute GVHD, 20 had grade I-II GVHD, and 7 had grade III-IV GVHD. Among the 3 patients with chronic GVHD, 1 experienced grade III-IV GVHD and 2 had grade I-II acute GVHD. Among the 14 patients with acute skin GVHD, 3 had grade III-IV, and among the 4 patients with acute gastrointestinal (GI) GVHD, 1 had grade III-IV. Of the 8 patients with acute skin +GI GVHD, 2 had grade III-IV. One patient experienced grade IV skin and liver GVHD. Of the 3 patients with chronic GVHD, 2 developed bronchiolitis obliterans and 1 had chronic skin GVHD. VOD developed in 2 patients. One of these patients had leukocyte adhesion deficiency (LAD) type 3 and underwent a transplant from an MUD without defibrotide. The other patient, diagnosed with HLH, received a haploidentical transplant with defibrotide. Two patients experienced secondary engraftment failure. One had thalassemia major, and the other had Chediak-Higashi syndrome. All patients except these two were followed-up with full donor chimerism. Four of the 57 patients died (overall mortality: 7 %). One patient with ALL died from GVHD-sepsis, and another died due to relapsed disease. One patient with AML was lost due to bronchiolitis obliterans during the third year post-transplant, and another patient with AML succumbed to sepsis and toxicity within the first 100 days. There were no deaths among patients with non-malignant diagnoses. The 100-day mortality rate was 1.75 %, with one patient passing away during this period.

Conclusions: Treosulfan can be preferred in the conditioning regimens of pediatric patients due to its similar efficacy and lower toxicity profile. Our study, which includes a broad pediatric patient group, provides guidance in this regard.

Keywords: Pediatric stem cell transplantation, treosulfan, treosulfan-based conditioning regimen

PDF View

References

  • Greystoke B, Bonanomi S, Carr TF,, Gharib M, Khalid T, Coussons M, et al. Treosulfan-containing regimens achieve high rates of engrafment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Heamatol. 2008;142(2)-257-62. google scholar
  • Dinur-Schejter Y, Krauss AC, Erlich O, Gorelik N, Yahel A, Porat I, et al. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning. Peditr Blood Cancer. 2015;62(2):299-304. google scholar
  • Burroughs LM, Shimamura A, Talano JA, Domm JA, Baker KK, Delaney C, et al. Allogeneic hematopoietic cell transplantation using treosulfan-based conditioning for treatment of marrow failure disorders. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2017;23(10):1669-77 google scholar
  • Burroughs LM, Nemecek ER, Torgerson TR, Storer BE, Talano JA, Domm J, et al. Treosulfan-based conditioning and hematopoietic cell transplantation for non-malignant diseases; a prospective multicenter trial. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2014;20(12):1996-2003. google scholar
  • Slatter MA, Rao K, Abd Hamid IJ, Nademi Z, Chiesa R, Elfeky R, et al. Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immundeficiency: UK Experience. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2018;24(3):529-36. google scholar
  • Brink MH, Zwaveling J, Swen JJ, Bredius RG, Lankester AC, Guchelaar HJ. Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discov Today. 2014;19(10):1572-1586. google scholar
  • Lüftinger R, Zubarovskaya N, Galimard JE, Cseh A, Salzer E, Locatelli F et al. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major. Annals of Hematol. 2022;101(3):655-665. google scholar
  • Romanski M, Wachowiak J, Glowka FK. Treosulfan pharmacokinetics and its variability in pediatric and adult patients undergoing conditioning prior to hematopoietic stem cell transplantation: current state of the art, in-depth analysis, and perspectives. Clin Pharmacokinet. 2018;57(10):1255-1265. google scholar
  • Buggia I, Locatelli F, Regazzi MB, Zecca M. Busulfan. Ann Pharmacother 1994;Sep28(9):1055-62 google scholar
  • Slattery JT, Risler LJ. Therapeutic drug monitoring of busulfan in haemotologic stem cell transplantation. Ther Drug Monit 1998;20(5):543-9. google scholar
  • Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005;35(3):233-41 google scholar
  • Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, et al. Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan / Fludarabine Conditioning. J Clin Oncol. 2010; 28(20): 3344-51. google scholar
  • Boztug H, Sykora KW, Slatter M, Zecca M, Veys P, Lankester A, et al. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents with Hematological Malignancies. Pediatr Blood Cancer. 2016; 63(1): 139-48. google scholar
  • Peccaroti J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT, et al. Sirolimus-Based Graft-Versus-Host Disease Prophylaxis Promotes the in Vivo Expansion of Regulatory T Cells and Permits Peripheral Blood Stem Cell Transplantation From Haploidentical Donors. Leukemia. 2015; 29(2): 396-405. google scholar
  • Cieri N, Greco R, Crucitti L, Morelli M, Giglio F, Levati G, et al. Post-Transplantation Cyclophosphamide and Sirolimus After Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. Biol Blood Marrow Transplant. 2015; 21(8): 1506-14. google scholar
  • Greco R, Lorentino F, Morelli M, Giglio F, Mannina D, Assanelli A, et al. Posttransplantation Cyclophosphamide and Sirolimus Prevention of GVHD After HLA-Matched PBSC Transplantation. Blood. 2016; 128(11): 1528-31. google scholar
  • Ploemacher RE, Johnson KW, Rombouts EJ, et al. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant 2004;10(4):236-45. google scholar
  • Koenigsmann M, Mohren M, Jentsch-Ulrich K, Etienne K, Westerhof GR, Baumgart J et al. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant 2004:34(6):477-83 google scholar
  • Cutting R, Mirelman A, Vora A. Treosulphan as an alternative to busulphan for myeloablative conditioning in pediatric allogeneic transplantation. Br J Haematol 2008;143(5):748-51 google scholar
  • Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A et al. Busulfan bioavailibility. Blood 1994;84(7):2144-50 google scholar
  • Galaup A, Paci A. Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. Expert opinion on Drug Metabolism and Toxicology. 2013;9(3):333-347 google scholar
  • Lazzari L, Ruggeri A, Stanghellini MT, Mastaglio S, Messina C, Giglio F et al. Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial. Frontiers in Oncol. 2021; 10(11): 731478. google scholar
  • Danielak D, Romanski M, Kasprzyk A Tezyk A, Glovka F. Population pharmacokinetic approach for evaluation of treosulfan and its active monoepoxide disposition in plasma and brain on the basis of a rat model. Pharmacological Reports 2020; 72(5):1297-1309 google scholar
  • Romanski M, Wachowiak J, Glowka FK. Treosulfan Pharmacokinetics and its variability in Pediatric and Adult Patients undergoing conditioning prior to hematopoietic stem cell transplantation: current state of the art, in dept analysis, and perspectives. Clin Pharmacokinet. 2018; 57(10): 1255-65. google scholar
  • Kalwak K, Mielcarek M, Patrick K, Styczynski J, Bader P, Corbacioglu S et al. Treosulfan-fludarabine-thiotepa-based conditioning before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. Bone Marrow Transplantation. 2020; 55(10) :1196-2007. google scholar
  • Haskaloglu Ş, Bal SK, İslamoğlu C, Altun D, Kendirli T, Dogu EF et al. Outcome of treosulfan-based reduced-toxicity conditioning regimens for HSCT in highrisk patients with primary immune deficiencies. Pediatric Transplantation. 2018; 22(7):e13266. google scholar
  • Suh JK, Im HJ, Kang SH, Kim H, Choi ES, Koh KN. Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant. 2022; 57(4): 681-684. google scholar
  • Mazon RO, Bueno D, Sisinni L, Mozo Y, Abad GC, Martinez AP. A retrospective stıdy of treosulfan versus busulfan-based conditioning in pediatric patients. Eur J Haematol. 2022; 109(5): 474-482. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Bayram, N., Yaman, Y., Özdilli, K., Odaman Al, I., Nepesov, S., Elli, M., & Anak, S.S. (2025). Treosulfan-Based Conditioning Regimen for Allogeneic Hepatopoietic Stem Cell Transplantation in Children: A Single Center Experience. Journal of Child, 25(1), 33-38. https://doi.org/10.26650/jchild.2025.1554292


AMA

Bayram N, Yaman Y, Özdilli K, Odaman Al I, Nepesov S, Elli M, Anak S S. Treosulfan-Based Conditioning Regimen for Allogeneic Hepatopoietic Stem Cell Transplantation in Children: A Single Center Experience. Journal of Child. 2025;25(1):33-38. https://doi.org/10.26650/jchild.2025.1554292


ABNT

Bayram, N.; Yaman, Y.; Özdilli, K.; Odaman Al, I.; Nepesov, S.; Elli, M.; Anak, S.S. Treosulfan-Based Conditioning Regimen for Allogeneic Hepatopoietic Stem Cell Transplantation in Children: A Single Center Experience. Journal of Child, [Publisher Location], v. 25, n. 1, p. 33-38, 2025.


Chicago: Author-Date Style

Bayram, Nihan, and Yöntem Yaman and Kürşat Özdilli and Işık Odaman Al and Serdar Nepesov and Murat Elli and Seniye Sema Anak. 2025. “Treosulfan-Based Conditioning Regimen for Allogeneic Hepatopoietic Stem Cell Transplantation in Children: A Single Center Experience.” Journal of Child 25, no. 1: 33-38. https://doi.org/10.26650/jchild.2025.1554292


Chicago: Humanities Style

Bayram, Nihan, and Yöntem Yaman and Kürşat Özdilli and Işık Odaman Al and Serdar Nepesov and Murat Elli and Seniye Sema Anak. “Treosulfan-Based Conditioning Regimen for Allogeneic Hepatopoietic Stem Cell Transplantation in Children: A Single Center Experience.” Journal of Child 25, no. 1 (Aug. 2025): 33-38. https://doi.org/10.26650/jchild.2025.1554292


Harvard: Australian Style

Bayram, N & Yaman, Y & Özdilli, K & Odaman Al, I & Nepesov, S & Elli, M & Anak, SS 2025, 'Treosulfan-Based Conditioning Regimen for Allogeneic Hepatopoietic Stem Cell Transplantation in Children: A Single Center Experience', Journal of Child, vol. 25, no. 1, pp. 33-38, viewed 12 Aug. 2025, https://doi.org/10.26650/jchild.2025.1554292


Harvard: Author-Date Style

Bayram, N. and Yaman, Y. and Özdilli, K. and Odaman Al, I. and Nepesov, S. and Elli, M. and Anak, S.S. (2025) ‘Treosulfan-Based Conditioning Regimen for Allogeneic Hepatopoietic Stem Cell Transplantation in Children: A Single Center Experience’, Journal of Child, 25(1), pp. 33-38. https://doi.org/10.26650/jchild.2025.1554292 (12 Aug. 2025).


MLA

Bayram, Nihan, and Yöntem Yaman and Kürşat Özdilli and Işık Odaman Al and Serdar Nepesov and Murat Elli and Seniye Sema Anak. “Treosulfan-Based Conditioning Regimen for Allogeneic Hepatopoietic Stem Cell Transplantation in Children: A Single Center Experience.” Journal of Child, vol. 25, no. 1, 2025, pp. 33-38. [Database Container], https://doi.org/10.26650/jchild.2025.1554292


Vancouver

Bayram N, Yaman Y, Özdilli K, Odaman Al I, Nepesov S, Elli M, Anak SS. Treosulfan-Based Conditioning Regimen for Allogeneic Hepatopoietic Stem Cell Transplantation in Children: A Single Center Experience. Journal of Child [Internet]. 12 Aug. 2025 [cited 12 Aug. 2025];25(1):33-38. Available from: https://doi.org/10.26650/jchild.2025.1554292 doi: 10.26650/jchild.2025.1554292


ISNAD

Bayram, Nihan - Yaman, Yöntem - Özdilli, Kürşat - Odaman Al, Işık - Nepesov, Serdar - Elli, Murat - Anak, SeniyeSema. “Treosulfan-Based Conditioning Regimen for Allogeneic Hepatopoietic Stem Cell Transplantation in Children: A Single Center Experience”. Journal of Child 25/1 (Aug. 2025): 33-38. https://doi.org/10.26650/jchild.2025.1554292



TIMELINE


Submitted23.09.2024
Accepted26.03.2025
Published Online08.07.2025

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE



Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.